Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Corporativo FraguaB de CVCGSBF 84 EV-to-EBITDA is 8.08 as of Jul. 25, 2026, which is 11% above its 10-year median of 7.30. GuruFocus rates CGSBF with a GF Score™ of 84/100 and a GF Value™ of $44.58. Among 507 Healthcare Providers & Services companies, Corporativo FraguaB de CV ranks better than 75.54% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Corporativo FraguaB de CV's enterprise value is $2,476 Mil.
Corporativo FraguaB de CV's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 was $306 Mil. Therefore, Corporativo FraguaB de CV's EV-to-EBITDA for today is 8.08.
The historical rank and industry rank for Corporativo FraguaB de CV's EV-to-EBITDA or its related term are showing as below:
CGSBF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 3.59 Med: 7.3 Max: 12.01
Current: 6.54
During the past 13 years, the highest EV-to-EBITDA of Corporativo FraguaB de CV was 12.01. The lowest was 3.59. And the median was 7.30.
CGSBF's EV-to-EBITDA is ranked better than 75.54% of 507
companies
in the Healthcare Providers & Services industry
Industry Median: 10.92
vs CGSBF: 6.54
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Corporativo FraguaB de CV (OTCPK:CGSBF) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Corporativo FraguaB de CV's PE Ratio (TTM) for today is calculated as:
Corporativo FraguaB de CV's share price for today is $29.66448.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Corporativo FraguaB de CV's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was $2.358.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Corporativo FraguaB de CV EV-to-EBITDA Competitor Comparison
For the Pharmaceutical Retailers subindustry, Corporativo FraguaB de CV's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Corporativo FraguaB de CV EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Corporativo FraguaB de CV's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Corporativo FraguaB de CV's EV-to-EBITDA falls into.
Corporativo FraguaB de CV's current Enterprise Value is $2,476 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Corporativo FraguaB de CV's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 was $306 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Corporativo FraguaB de CV (CGSBF) has a EV-to-EBITDA of 8.08 as of Jul. 25, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Corporativo FraguaB de CV. This is 11% above median its historical median of 7.30. Over the past decade, Corporativo FraguaB de CV's EV-to-EBITDA has ranged from 3.59 to 12.01. According to the industry distribution chart, Corporativo FraguaB de CV ranks #124 out of 507 companies in the Healthcare Providers & Services industry, placing it in the top 24.5%.
Is Corporativo FraguaB de CV's EV-to-EBITDA too high?
Corporativo FraguaB de CV's current EV-to-EBITDA of 8.08 is 11% above median its 10-year median of 7.30. Over the past 10 years, this metric has ranged from a low of 3.59 to a high of 12.01. The Healthcare Providers & Services industry median EV-to-EBITDA is 10.92. Corporativo FraguaB de CV's value of 8.08 is 26% below this industry median. Based on the distribution chart, Corporativo FraguaB de CV ranks #124 out of 507 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Corporativo FraguaB de CV has a GF Score™ of 84/100, reflecting its overall financial health beyond just this single metric.
How does Corporativo FraguaB de CV's EV-to-EBITDA compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Corporativo FraguaB de CV ranks #124 out of 507 companies for EV-to-EBITDA. This places Corporativo FraguaB de CV in the top 25% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 10.92. Corporativo FraguaB de CV's value of 8.08 is 26% below this benchmark. Historically, Corporativo FraguaB de CV's own EV-to-EBITDA has ranged from 3.59 to 12.01 over the past decade. While the company's 10-year median is 7.30 vs. the industry median of 10.92, Corporativo FraguaB de CV has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 10.92, based on 507 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Corporativo FraguaB de CV's current EV-to-EBITDA of 8.08 is 26% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Corporativo FraguaB de CV. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 10.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Corporativo FraguaB de CV's current EV-to-EBITDA is 8.08, which is 11% above median its own 10-year median of 7.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corporativo FraguaB de CV stock overvalued right now?
Corporativo FraguaB de CV (CGSBF) has a current EV-to-EBITDA of 8.08. The stock's GF Value™ is $44.58, compared to a current price of $29.66 — trading 33.5% below its estimated fair value. The current EV-to-EBITDA is 8.08, which is 11% above median its 10-year median of 7.30 and 26% below the Healthcare Providers & Services industry median of 10.92. Corporativo FraguaB de CV's overall GF Score™ is 84/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Corporativo FraguaB de CV (CGSBF), the current EV-to-EBITDA is 8.08 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Corporativo FraguaB de CV (CGSBF) Overvalued in 2026?
Based on GuruFocus' analysis, Corporativo FraguaB de CV stock appears to be undervalued.
The current stock price of $29.66 is trading 33.5% below its estimated GF Value™ of $44.58.
Key valuation signals for CGSBF:
EV-to-EBITDA: 8.08 (11% above median its 10-year median of 7.30)
GF Value™: $44.58 vs. price of $29.66 (33.5% below fair value)
Industry Position: 26% below the Healthcare Providers & Services median (#124 of 507)
No single metric tells the full story. See the CGSBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Corporativo Fragua SAB de CV is engaged in the drug retail sector in Mexico. The company operates a network of pharmacies under the SuperFarmacia brand name, focusing on selling medicines, medical devices, and a variety of other products, including grocery items, exercise machines, perfumes, housewares, electronics, personal care products, toys, and photographic equipment.
84GF Score
Get the complete analysis for CGSBF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CGSBF has been successfully added to your 
